Biomarker evidence of Alzheimer pathology

      Alzheimer's disease, senile dementia, atherosclerosis, senile dementia of the Alzheimer's type, NINCDS-ADRDA probable Alzheimer's disease, IWG prodromal Alzheimer's disease, NIA-AA preclinical Alzheimer's disease, IWG2 at risk for Alzheimer's disease… This disease has been in dynamic re-definition for the past 115 years. Biomarkers of AD pathology have allowed to perform an “in vivo neuropathology” and demonstrate the presence of brain pathology long before any sign of cognitive deterioration, and possibly even in persons who will never develop cognitive deterioration. In persons with cognitive impairment, this has provided the unprecedented opportunity of an accurate molecular diagnosis and paved the way to personalised pathology-based interventions. In persons with no cognitive impairment, the detection of pathology is not accompanied by the prediction of when, and even if, cognitive impairment will develop. This uncertainty must be sorted out for biomarkers to be used appropriately and safely in this population and for the very concept of Alzheimer's disease to be fleshed out once and for all.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect